The Attributable Morbidity and Mortality of Ventilator-Associated Pneumonia in the Critically Ill Patient

Transcription

1 The Attributable Morbidity and Mortality of Ventilator-Associated Pneumonia in the Critically Ill Patient DAREN K. HEYLAND, DEBORAH J. COOK, LAUREN GRIFFITH, SEAN P. KEENAN, and CHRISTIAN BRUN-BUISSON for the Canadian Critical Care Trials Group Department of Medicine, Queen s University, Kingston; Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton; University of Western Ontario, London Health Sciences Center, London, Ontario, Canada; and Service de Réanimation Médicale and Unité d Hygiène-Prévention de l Infection, Hôpital Henri Mondor, Créteil, France To evaluate the attributable morbidity and mortality of ventilator-associated pneumonia (VAP) in intensive care unit (ICU) patients, we conducted a prospective, matched cohort study. Patients expected to be ventilated for 48 h were prospectively followed for the development of VAP. To determine the excess ICU stay and mortality attributable to VAP, we matched patients with VAP to patients who did not develop clinically suspected pneumonia. We also conducted sensitivity analyses to examine the effect of different populations, onset of pneumonia, diagnostic criteria, causative organisms, and adequacy of empiric treatment on the outcome of VAP. One hundred and seventyseven patients developed VAP. As compared with matched patients who did not develop VAP, patients with VAP stayed in the ICU for 4.3 d (95% confidence interval [CI]: 1.5 to 7.0 d) longer and had a trend toward an increase in risk of death (absolute risk increase: 5.8%; 95% CI: 2.4 to 14.0 d; relative risk (RR) increase: 32.3%; 95% CI: 20.6 to 85.1%). The attributable ICU length of stay was longer for medical than for surgical patients (6.5 versus 0.7 d, p 0.004), and for patients infected with high risk organisms as compared with low risk organisms (9.1 d versus 2.9 d). The attributable mortality was higher for medical patients than for surgical patients (RR increase of 65% versus 27.3%, p 0.04). Results were similar for three different VAP diagnostic criteria. We conclude that VAP prolongs ICU length of stay and may increase the risk of death in critically ill patients. The attributable risk of VAP appears to vary with patient population and infecting organism. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C, for the Canadian Critical Care Trials Group. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. AM J RESPIR CRIT CARE MED 1999;159: (Received in original form July 10, 1998 and in revised form November 19, 1998) Supported in part by grants from the Ontario Thoracic Society, Medical Research Council of Canada, Hoescht Marion Rousell, and the Boston Scientific Corporation. Drs. Heyland and Cook are Career Scientists with the Ontario Ministry of Health. Dr. Keenan is supported by a fellowship from the Canadian Lung Association and Medical Research Council. Correspondence and requests for reprints should be addressed to Dr. D. K. Heyland, Angada 3, Kingston General Hospital, 76 Stuart Street, Kingston, ON, K7L 2V7 Canada. dkh2@post.queensu.ca Am J Respir Crit Care Med Vol 159. pp , 1999 Internet address: Although numerous studies have shown that ventilator-associated pneumonia (VAP) frequently complicates the course of patients in the intensive care unit (ICU) (1 5), the question of whether or not critically ill patients are at increased risk of death or prolonged ICU stay as a result of acquiring pneumonia remains controversial. Studies of fatality rates among patients with VAP as compared with patients without VAP have generated the contradictory conclusions that VAP does (6 8) and does not (1, 9) increase morbidity and mortality. Other studies, using univariate analysis, have suggested that VAP is associated with an increased risk of fatality, but this association was not evident in multivariate analyses (3, 10). The use of stepwise logistic regression to control for effects of confounding variables has shown VAP to significantly increase the risk of death in the ICU (5, 11). Using a rigorous method of matching patients with pneumonia to patients without pneumonia, one study concluded that VAP probably does increase the risk of death (12), whereas another study found that VAP does not increase mortality (13). Previous analyses of the attributable morbidity and mortality of VAP have yielded conflicting results. Diverse study designs, modest sample sizes, and different definitions of VAP have made interpretation of this literature challenging. Variables that may influence the extent to which VAP increases morbidity or mortality include the affected patient population, timing of onset of pneumonia, diagnostic strategy, causative organism, and adequacy of initial therapy. We determined the clinical consequences of VAP in a large, prospectively collected data base of ICU patients at risk for VAP. Our objective was to determine, with a rigorous matching scheme, the attributable length of stay and mortality associated with VAP.

2 1250 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL METHODS Our study was conducted in the context of a multicenter, randomized trial in which the effects of sucralfate and those of ranitidine were compared in mechanically ventilated, critically ill patients (14). In 15 university affiliated ICUs across Canada, patients ventilated for more than 48 h who had no evidence of pneumonia or gastrointestinal bleeding on admission were enrolled, and were followed daily until death or discharge. Age, sex, admission diagnosis, location prior to the ICU, and admission acute physiology and chronic health evaluation II (APACHE II) score (15) were recorded at baseline. Patients were monitored daily for the development of gastrointestinal bleeding and VAP; multiple organ dysfunction (MOD) scores were also recorded daily (16). Ethics approval was obtained from the institutional review board of each participating site, and informed consent was obtained from patients or their surrogates. All study patients who had clinically suspected pneumonia were to undergo bronchoscopy with either collection of a protected brush catheter (PBC) specimen or bronchoaveloar lavage (BAL) to diagnose VAP. Clinically suspected pneumonia was defined as the finding of radiographic features suggestive of pneumonia with no other obvious cause, and the presence of any two of the following: fever 38 C, leukocytosis ( /L), or relative neutropenia ( /L), purulent sputum or a change in character of sputum, isolation of pathogenic bacteria from sputum, and an increasing alveolar arterial oxygen gradient. An adjudication committee, blinded to patients treatment allocation and study outcomes, reviewed pertinent clinical, microbiologic, laboratory, and pathologic reports to determine the final outcome status of all patients with clinically suspected pneumonia. In some cases, patients were assessed as having VAP even though bronchoscopic techniques yielded less than significant growth on culture. Decisions of the adjudication committee about the presence or absence of VAP were based on the total constellation of signs, symptoms, and ancillary data. All events were given duplicate, independent reviews; differences were resolved by consensus. All decisions about VAP and general preventive and therapeutic patient management were made by the ICU team at each center. Statistical Analysis To determine the attributable morbidity and mortality of VAP, we utilized a matching procedure (similar to the procedure we used in a previous study [17]) with a weighting schema to ensure that patients with an adjudicated diagnosis of pneumonia were similar in every way except for the event of interest to patients who did not have VAP. Only patients who did not develop clinically suspected pneumonia were considered for the control group. The criteria used in our matching procedure were based on variables considered to be important determinants of length of stay and mortality. Given that the conflicting results of previous analyses (12, 13) may be partly explicable on the basis of differences in patient population, we also matched patients and controls on medical or surgical status upon admission to the ICU. To determine attributable length of stay, we used 10 criteria to determine the best match for a case. A control had to match a patient in the following criteria in order to be considered a possible match: mortality status, medical/surgical status, time in ICU prior to the development of VAP, duration of mechanical ventilation prior to VAP, Day 1 APACHE II score ( 4 points), and MOD score on the day prior to development of VAP ( 3 points). For each control, the remaining four criteria were weighted with regard to their importance (to reflect the extent to which each criterion [covariate] might influence outcome): (1) ICU admitting diagnosis: 8 points; (2) age 15 yr: 4 points; (3) center at which treated: 2 points; and (4) gender: 1 point. The overall score was the sum of the points for which the control matched the characteristics of the case. Among the potential control subjects who met the must match criteria, the subject with the highest score was matched to the case. Thus, if one potential control subject had the same admission diagnosis as a case (8 points) and another matched the case on all the less important criteria (a total of 7 points), the control subject matching by admission diagnosis status had the higher score. In the case of a tie, the control subject with the closest APACHE II score was chosen. If there was still a tie, the control closest in age to the case was chosen. Once the controls were chosen, they were taken out of the pool of possible matches for the remaining cases. The additional length of stay attributable to VAP was estimated from the average difference in stay for all matched pairs (case versus control), which was tested statistically with a paired t test; this was also done separately for pairs that survived and those that died. To determine mortality attributable to VAP, we used the same matching procedure as described previously, except that we deleted mortality status as a matching criterion. The attributable mortality was estimated as the proportion of the crude mortality that was attributable to VAP (i.e., (crude mortality cases Crude Mortality controls )/ crude mortality controls ) reported as the relative risk increase (RRI) in mortality. The confidence interval (CI) for the attributable mortality and the statistical test for determining whether it was different from zero were based on the large sample variance proposed by Leu and coworkers (18), as derived from the work of Kuritz and Landis (19). We also performed several a priori sensitivity analyses. To determine the influence of differing patient populations on VAP outcome, we performed two separate subgroup analyses in which we compared the results for medical and surgical patients and trauma and nontrauma patients. To determine the influence of timing of onset of pneumonia, we compared the results for patients with early-onset VAP ( 7 d) with those of patients with late-onset pneumonia ( 7 d after ICU admission). We used a cutoff of 7 d because it corresponds to the median time of occurence of pneumonia in our data base, and because mechanical ventilation lasting 7 d or more is associated with increased likelihood of infection with a high risk organism (20). To explore the effect of different diagnostic strategies for determining the presence or absence of VAP, we examined the results of the analysis when cases were defined by: (1) the adjudication committee; (2) a positive culture with a significant concentration of organisms from invasive bronchoscopic testing ( 10 3 for the PBC technique and 10 4 for BAL); and (3) criteria for clinically suspected pneumonia as determined by the bedside intensivist. To determine the influence of different organisms associated with VAP, we classified causative organisms on the basis of their potential to develop multidrug resistance (as previously defined [20]). High risk organisms included Pseudomonas species, Acinetobacter, Stenotrophomonas, and methicillin-resistant Staphylococcus aureus. Low risk organisms included all others (we did not consider Candida a pathogen in our immunocompetent population). Additionally, to determine whether the adequacy of empiric antibiotic therapy (21) influenced attributable risk, we compared patients receiving appropriate and inappropriate empiric antibiotics. To determine the adequacy of empiric antibiotics, charts were reviewed independently and categorizations were made after dicussions among three of us (D.J.C., S.K., D.K.H.). In this determination we focused on whether a patient s empiric antibiotics had activity against each organism isolated, rather than examining dosing schedules. Initial antibiotics (prescribed within 48 h after the onset of clinically suspected of pneumonia) were considered appropriate if at least one such antibiotic had activity against the organism(s) that subsequently grew on cultures (except in the case of Pseudomonas, for which appropriate initial therapy required two antibiotics with activity against the organism). RESULTS Twelve hundred critically ill patients, recruited to participate in a randomized trial of stress ulcer prophylaxis, were followed daily for the development of VAP. We excluded 186 patients who died, were discharged, or had VAP occurring within the first 48 h after ICU admission. Of the remaining 1,014 patients, 250 (24.7%) developed clinically suspected VAP. Of these, 186 (74.4%) underwent bronchoscopy and had a specimen collected with the PBC technique or underwent BAL. After a review of pertinent patient data, 177 patients were judged to have VAP. The median duration from admission to the onset of VAP was 7 d (interquartile range: 5 to 10 d). Organisms implicated in the etiology of VAP are shown in Table 1. Using our matching algorithm, we found suitable matches for 164 of the 177 (93%) cases of VAP in the attributable lengthof-stay analysis, and for 173 of the 177 (98%) cases in the at-

3 Heyland, Cook, Griffith, et al.: Consequences of Ventilator-Associated Pneumonia 1251 TABLE 1 ORGANISMS ASSOCIATED WITH VENTILATOR-ASSOCIATED PNEUMONIA IN STUDY PATIENTS Organism No. Patients (%) Gram-negative bacilli Escherichia coli 17 (9.8) Klebsiella 15 (8.7) Enterobacter/Citrobacter 21 (12.1) Serratia 5 (2.9) Proteus/Providencia 9 (5.2) Acinetobacter 6 (3.5) Pseudomonas 38 (22.0) Hemophilus 45 (26.0) Other gram-negative bacilli 18 (10.4) All gram-negative bacilli 123 (71.1) Gram-positive cocci Streptococcus pneumoniae 14 (8.1) Staphylococcus aureus* 64 (37.0) Other gram-positive cocci 33 (19.1) All gram-positive cocci 91 (52.6) Gram-positive bacilli 5 (2.9) Gram-negative cocci 13 (7.5) Anaerobes 1 (0.6) Candida/yeast 26 (15.0) Mixed oropharyngeal flora 9 (5.2) Other 12 (6.9) No growth 5 (2.9) * Four cases of Staphylococcus aureus were methicillin-resistant. Organisms shown are those isolated from endotracheal aspirates, protected brush, or bronchoalveolar lavage from matched patients with adjudicated ventilator-associated pneumonia (n 173). The total number of organisms is more than the number of patients because several patients had more than one isolate. tributable mortality analysis. Baseline characteristics of patients with VAP and their matched controls were similar, and are shown in Table 2. Our matching procedure estimated the ICU length of stay attributable to VAP to be 4.7 d (95% CI: 2.0 to 7.5 d) in those patients who survived, and 2.6 d (95% CI: 5.6 to 10.7 d) in patients who died, for an average of 4.3 d in all patients (95% CI: 1.5 to 7.0 d, p 0.001). The crude mortality rates for cases and controls were 41 of 173 (23.7%) and 31 of 173 (17.9%), respectively (absolute attributable mortality of 5.8%, 95% CI: 2.4 to 14.0). The RRI attributable to VAP was 32.3% (95% CI: 20.6 to 85.1%). The crude mortality rates for each subgroup are shown in Table 3. In medical patients, the attributable ICU length of stay was greater (6.5 d versus 0.7 d, p 0.04) and the attributable mortality was greater (65% versus 27.3% RRI, p 0.04) than in surgical patients. Differences in baseline demographics and study outcomes between medical and surgical patients are shown in Table 4. There was no difference in attributable length of stay or mortality between trauma and nontrauma patients or between those with and early-onset and late-onset pneumonia (Table 5). When different diagnostic criteria were used to ascertain the presence or absence of pneumonia, there was no statistically significant change in the results (Table 5). The attributable length of stay due to VAP associated with high risk organisms was longer than the attributable length of stay for VAP due to low risk organisms (9.1 d versus 2.9 d, p 0.06), although the attributable mortality was similar in the two groups. There were no differences in attributable morbidity or mortality from VAP treated empirically with appropriate versus inappropriate antibiotics (Table 5). DISCUSSION In this prospective study, we compared patients with VAP and matched controls, and found that VAP is associated with an excess ICU length of stay and a trend toward increased risk of death. Our sample size allowed us to explore the influence of several covariates on attributable morbidity and mortality of VAP. The ICU length of stay and mortality were greater for medical than for surgical patients with VAP. The attributable length of ICU stay was greater for patients with high risk organisms than for those with low risk organisms. Results were TABLE 2 BASELINE CHARACTERISTICS AND CRUDE OUTCOMES OF STUDY PATIENTS Characteristic Patients with VAP (n 173) Patients without VAP (n 173) p Value Mean age (SD), yr 55.1 (19.6) 55.9 (19.0) 0.7 Female, n (%) 58 (34) 73 (42) 0.1 Admission diagnosis 0.72 Cardiac, n (%) 40 (23.1) 41 (23.7) Respiratory, n (%) 23 (13.3) 25 (14.5) Gastrointestinal, n (%) 4 (2.3) 3 (1.7) Neurologic, n (%) 39 (22.5) 41 (23.7) Sepsis, n (%) 5 (2.9) 7 (5.2) Burns, n (%) 7 (4.1) 2 (1.2) Trauma, n (%) 29 (16.8) 26 (15.0) Postoperative, n (%) 18 (10.4) 16 (9.2) Other, n (%) 8 (4.6) 6 (3.3) Mean APACHE II score (SD) 24.1 (6.2) 24.2 (5.7) 0.9 Mean MOD score (SD) 6.0 (2.7) 5.5 (2.8) 0.07 Receiving antibiotics at study entry (%) 116 (67) 157 (90.8) Duration of mechanical ventilation (d*) 16 (12, 24) 13 (9, 23) Length of stay in ICU (d*) 19 (14, 26) 14 (10, 24) Crude mortality (%) 41 (23.7) 31 (17.7) 0.19 Definition of abbreviations: APACHE Acute Physiology and Chronic Health Evaluation; MOD multiorgan dysfunction; VAP ventilator-associated pneumonia. * Median and interquartile range. Baseline and demographic characteristics of cases (patients with VAP) and matched controls (patients without VAP) for mortality analysis. The baseline demographics of cases and controls were similar for the attributable length-of-stay analysis.

4 1252 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL TABLE 3 ABSOLUTE MORTALITY RATES IN VARIOUS SUBGROUPS Cases n (%) Controls n (%) Different patient populations Medical patients (n 107) 33 (30.8) 20 (18.7) Surgical patients (n 66) 8 (12.1) 11 (16.7) Trauma (n 33) 3 (9.1) 2 (6.1) Nontrauma (n 140) 38 (27.1) 29 (20.7) Onset of VAP Early ( 7 d) (n 67) 16 (23.9) 12 (17.9) Late ( 7 d) (n 106) 25 (23.6) 19 (17.9) Method of diagnosis Adjudication (n 173) 41 (23.7) 31 (17.9) PBC/BAL positive (n 86) 19 (22.1) 17 (19.8) Clinical suspicion (n 239) 55 (23.0) 43 (18.0) Type of organism High risk (n 40) 8 (20.0) 6 (30.0) Low risk (n 133) 33 (24.8) 25 (18.8) Empiric antibiotics Appropriate (n 111) 24 (22.2) 20 (18.5) Inappropriate (n 31) 8 (26.7) 5 (16.7) Definition of abbreviations: BAL bronchoalveolar lavage; PBC protected brush catheter; VAP ventilator-associated pneumonia. similar for trauma and nontrauma patients, for patients with early versus late onset pneumonia, for three different VAP diagnostic strategies, and for VAP treated empirically with appropriate and inappropriate antibiotics. The relationship between late-onset pneumonia, high-risk organisms, and inappropriate empiric antibiotics is difficult to clarify. Late-onset pneumonia may carry a higher risk of morbidity and mortality, probably because cases are often caused by resistant organisms, which are difficult to treat, and may result in delayed or ineffective antibiotic therapy. In several studies, VAP caused by Pseudomonas, Acinetobacter, and methicillin-resistant S. aureus has been associated with increased mortality (12, 22, 23). Likewise, recent observational studies suggest that the appropriateness of early empiric antibiotic therapy is an important prognostic factor in VAP (21, 24). However, the influence of time of onset of pneumonia per se, relative to other confounding factors such as multidrug resistance and/or inappropriate antibiotics, is unclear (9). In our analysis we were able to find an effect of high-risk organisms on outcome; however, the results of our sensitivity analysis do not show that patients with late-onset pneumonia had greater mortality than those with early-onset pneumonia. This latter finding is consistent with the findings reported by Mosconi and colleagues, who compared patients with early- and lateonset pneumonia and found a similar risk of death in both groups (25). Likewise, patients given inappropriate empiric antibiotics had outcomes similar to those of as patients receiving appropriate empiric therapy. However, given the small number of patients receiving inappropriate antibiotics (n 31) in our study, the inferences from analysis of this subgroup weak and inconclusive. A multivariate analysis of a large cohort of patients with VAP would better determine the respective influence of time of onset of pneumonia, appropriateness of antibiotic therapy, and high risk organisms on outcome. Six studies have utilized a matching procedure to determine the morbidity and mortality attributable to pneumonia in ICU patients (Table 6). Our results differ from those of Papazian and coworkers (13) and Baker and associates (27), but are consistent with those of other studies (12, 28 30) (Table 6). Fagon and colleagues (12) matched 48 ICU patients (predominantly medical) with VAP (diagnosed through BAL or the PBC technique) with controls for age, simplified acute TABLE 4 BASELINE CHARACTERISTICS AND CRUDE OUTCOMES OF MEDICAL AND SURGICAL PATIENTS Characteristic Medical Patients with VAP (n 108) Surgical Patients with VAP (n 69) p Value Mean age (SD) 53.3 (20.3) 58.0 (18.2) 0.13 Female, n (%) 42 (39) 16 (24) 0.04 Admission diagnosis Cardiac, n (%) 15 (13.9) 25 (36.2) Respiratory, n (%) 23 (21.3) 0 Gastrointestinal, n (%) 4 (3.7) 0 Neurologic, n (%) 30 (27.7) 9 (13.0) Sepsis, n (%) 5 (4.6) 0 Burns, n (%) 7 (6.5) 0 Trauma, n (%) 19 (17.6) 10 (14.5) Surgical, n (%) 0 18 (26.1) Other, n (%) 4 (3.7) 4 (2.5) Mean APACHE II Score (SD) 24.8 (6.4) 23.0 (5.7) Mean MOD score (SD) 6.1 (3.0) 5.7 (2.2) 0.37 Receiving antibiotics at study entry (%) 62 (58) 54 (82) Day in ICU when pneumonia developed (d*) Duration of mechanical 7 (5, 9) 7 (5, 12) 0.41 ventilation (d*) 17 (12, 25) 16 (12, 24) 0.68 Length of stay in ICU (d*) 20 (13, 26) 19 (14, 27) 0.48 Crude mortality (%) 33 (30.8) 8 (12.1) Definition of abbreviations: APACHE Acute Physiology and Chronic Health Evaluation; ICU intensive care unit; MOD multiorgan dysfunction; VAP ventilator-associated pneumonia. * Median and interquartile range.

5 Heyland, Cook, Griffith, et al.: Consequences of Ventilator-Associated Pneumonia 1253 TABLE 5 RESULTS OF SENSITIVITY ANALYSES Attributable Length of Stay Mean (95% CI) Attributable Mortality RRI (95% CI) Different patient populations Medical patients (n 108) 6.5 ( ) 65.0 ( ) Surgical patients (n 69) 0.7 ( )* 27.3 ( )* Trauma (n 35) 3.8 ( ) 50.0 ( ) Nontrauma (n 142) 4.4 ( ) 31.0 ( ) Onset of VAP Early ( 7 d) (n 68) 6.5 ( ) 33.3 ( ) Late ( 7 d) (n 109) 2.8 ( ) 31.6 ( ) Method of diagnosis Adjudication (n 177) 4.3 ( ) 32.3 ( ) PBC/BAL positive (n 87) 4.5 ( ) 11.8 ( ) Clinical suspicion (n 250) 4.7 ( ) 27.9 ( ) Type of organism High risk (n 42) 9.1 ( ) 33.3 ( ) Low risk (n 135) 2.9 ( ) 32.0 ( ) Empiric antibiotics Appropriate (n 111) 6.2 ( ) 20.0 ( ) Inappropriate (n 31) 3.7 ( ) 60.0 ( ) Definition of abbreviations: BAL bronchoalveolar lavage; CI confidence interval; PBC protected brush catheter; RRI relative risk increase; VAP ventilator-associated pneumonia. * Medical versus surgical, p p p physiology score, indication for ventilatory support, date of admission, and duration of ICU stay prior to onset of VAP. In this retrospective study, VAP was associated with an increased risk of death (odds ratio [OR]: 2.0; 95%CI: 1.61 to 2.49), and the mean length of stay of cases was 34 d, as compared with 21 d for controls (p 0.02). The increased attributable mortality in Fagon and colleagues study relative to the results of our study may be due to differences in empiric treatments and causative organisms. Previous research by Fagon and associates found that patients with VAP were more likely to receive inappropriate initial therapy (26) and/or to be infected with high risk organisms (20) than the patients in our setting. Baker and colleagues retrospectively identified 62 trauma patients with clinically suspected pneumonia who underwent bronchoscopy with the PBC technique or BAL (27). Thirty patients with a positive BAL or PBC result were matched with patients of similar age, sex, severity of illness, and number of discharge diagnoses. In this population there was a trend toward prolonged ICU stay (20 d versus 15 d, p 0.16), but no difference in mortality (24% versus 24%). In another study, patients admitted to a surgical ICU and a medical/respiratory ICU who developed VAP were identified prospectively and matched with control patients. The only criteria used to match patients was admission to the same ICU during the same time period (28). Attributable duration of ICU stay was not reported. Mortality rates were significantly higher among patients with VAP than among controls (55% versus 5% for surgical ICU patients and 55% versus 7.5% for medical/respiratory ICU patients, p for both comparisons). The lack of adequate matching limits the inferences that can be drawn from this study. Craig and coworkers (29) studied a large group of ICU patients (n 670) and matched those that developed pneumonia in the ICU (n 54) with those that did not on the basis of the following criteria: age ( 2 yr), sex, admission diagnosis, risk factors for pneumonia, and surgical procedure. They found that patients with pneumonia stayed three times longer in the ICU (12 d versus 4.3 d, p 0.001) and had a 4-fold greater mortality than controls (20.3% versus 5.6%, p 0.001). Not all study patients were ventilated, and the duration of ICU stay prior to onset of pneumonia was not considered in this study. The adequacy of the matching was questionable, since patients with pneumonia had more risk factors for pneumonia than did patients who did not develop pneumonia. In addition, only clinical criteria were used to diagnose pneumonia. Kappstein and colleagues (30) prospectively followed 270 consecutive ICU patients for the development of pneumonia, matching cases (patients who developed VAP) with controls (patients who did not). However, they excluded cases in which the patient died (21 of 78, or 26.9%) and cases for whom no suitable control could be found (23% or 29.5%). The mean excess length of ICU stay was 10 d, but mortality attributable to VAP was not reported. That over half of Kappstein and colleagues cases were not matched weakens the inferences one can make from their study. Papazian and colleagues (13) examined the excess mortality and length of both ICU and hospital stay for 85 patients with VAP diagnosed through the PBC technique compared with controls matched on the basis of diagnosis, indication for ventilation, age, sex, and APACHE score. In addition, the control had to have been ventilated for at least as long as the case patient prior to the onset of VAP. Mortality was similar among cases (40%) and controls (38.8%). The duration of mechanical ventilation and ICU stay was significantly longer in cases than in controls (21 d versus 16 d and 26 d versus 21 d, respectively). Differences in results across these studies may be partly explained by differences in patients, methods, and diagnostic strategies. As with to our approach, Papazian and coworkers did not include patients in their control group with clinically suspected pneumonia that did not have a confirmed diagnosis,

6 1254 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL TABLE 6 STUDIES OF ATTRIBUTABLE MORBIDITY AND MORTALITY OF VENTILATOR-ASSOCIATED PNEUMONIA IN INTENSIVE-CARE-UNIT PATIENTS Study (Reference) Patients Methods Diagnosis of Pneumonia ICU Length of Stay (d) ICU Mortality Cases Controls Cases Controls Fagon and colleagues, 48 patients Retrospective case Required 34* 21* 26/48 (54%) 13/48 (27%) 1993 (12) ventilated 72 h control; same positive PBC p 0.01 with VAP; 48 indication for or 5% 21 (4, 175) 15 (3, 88) matched pairs ventilation, age, SAPS, intracellular p 0.02 prior length of bacteria exposure, within 2 yr. (Control group included patients with CSP and negative PBC) Baker and colleagues, 30 intubated Retrospective case Positive BAL 20 (14, 32) 15 (7, 26) 24% 24% 1996 (27) trauma patients control. Controls or PBC p 0.16 matched by age, sex, severity of illness, and number of discharge diagnoses Cunnion and colleagues, 40 patients from Cases identified by CDC criteria; Not reported SICU 1996 (28) SICU and M/RCU prospective surveillance. clinical plus 55% 5% Controls identified X-ray M/RICU retrospectively; 55% 7.5% matched by time of admission to ICU only Craig and Connelly, 54 ICU patients, Cases identified by Clinical 12 (7.5)* 4.3 (3.3)* 11/54 (20.3%) 3.54 (5.6%) 1984 (29) not all ventilated prospective surveillance. criteria plus p p 0.05 Controls identified X-ray retrospectively. Cases matched to more than one control by diagnosis, age, sex, host factors, surgical procedure. Excluded patients who died from LOS analysis Kappstein and colleagues, 78 developed Prospective cohort study; CDC criteria; Additional ICU stay Not done 1992 (30) VAP; patients were cases matched to more clinical and excluded who died than one control; X-ray 10 (21)* from analysis; only matched by indication for 34 matched ventilation; age, prior patients length of exposure 5.5 (1.5, 12.4) Papazian and colleagues, 97 patients Prospective matched Required 32.9 (26.4)* 24.5 (16.6)* 34/85 (40%) 33/85 (38.8%) 1996 (13) ventilated 48 h cohort; same diagnosis, positive PBC p NS with VAP; 85 indication for ventilation, 26 (3, 152) 21 (3, 84) matched pairs age, APACHE score, prior p 0.05 length of exposure, within 1 yr. (Control group did not include patients with CSP and negative PBC) Definition of abbreviations: CDC Centers for Disease Control and Prevention; CSP clinical suspicion of pneumonia; ICU intensive care unit; M/RICU medical and respiratory intensive care unit; PBC protected brush catheter; SAPS Scale for the Assessment of Positive Symptoms; SICU surgical intensive care; VAP ventilator-associated pneumonia. * Mean (standard deviation). Median (range). whereas Fagon and associates included such patients as potential controls. Our matching strategy was similar to that of others (12, 13) in that we included prior duration of stay in the ICU as a matching criterion. However, our approach differed from that in all other studies in that we matched cases and controls according to daily assessment of organ dysfunction. We used the MOD score, a time-dependent variable that has been shown to discriminate patients who are likely to survive from those who are not (16). Matching only on the basis of variables measured at baseline may result in unequal groups, given that pneumonia, on average, occurs approximately 7 d after admission to the ICU. Patients developing VAP after their ICU admission may be at greater risk of infection because of persisting organ failure and severity of disease, whereas controls matched only according to disease severity at admission may have a more favorable evolution; thus assessment of the morbidity caused by an event occurring 7 d after admission may lead to overestimation of VAP-associated

7 Heyland, Cook, Griffith, et al.: Consequences of Ventilator-Associated Pneumonia 1255 morbidity. Therefore, we used a time-dependent variable and measured its value more proximate to the onset of pneumonia in order to enhance the comparability of cases and controls. In this study we matched cases and controls according to severity of organ dysfunction on the day prior to clinical suspicion of pneumonia. Conversely, the selection of the day before development of clinically suspected pneumonia may be viewed as too close to the event studied, since cases may already have an increased risk of poor outcome because of incipient pneumonia, which may lead to underestimation of attributable risk. However, our results were similar when we matched cases and controls on the basis of severity of organ dysfunction 3 d before the onset of VAP (data not shown). An important difference among the studies being discussed here is in the criteria used to diagnose pneumonia. In both the French studies (12, 13) and the study by Baker and colleagues (27), bronchoscopy with a protected brush catheter and a specimen that yielded 10 3 cfu/ml were required to make the diagnosis. In our study, 187 of 250 (75%) patients with clinically suspected pneumonia underwent bronchoscopy with either a protected brush catheter or BAL, of whom 87 (46%) had VAP confirmed according to the usual criteria for these techniques. However, the majority of patients were already receiving antibiotics at the time of diagnosis. Given the uncertainty about the accuracy of invasive diagnostic techniques in patients already receiving antibiotics (31, 32), we used an adjudication committee to determine the final diagnosis of pneumonia, but examined attributable length of stay and mortality according to three different definitions in the sensitivity analysis. We found that results for attributable length of stay and mortality were similar regardless of diagnostic approach. With a larger sample size, differences between the different diagnostic methods might be discernible. However, our findings are consistent with the finding by Timsit and colleagues that attributable morbidity and mortality were the same in patients with clinically suspected pneumonia and patients with a bacteriologically confirmed diagnosis (33). Differences in the proportion of medical and surgical patients in each study may also explain discrepant results. The two studies that showed no attributable risk of dying enrolled no medical patients (27) and only 26% medical patients (13), respectively. This contrasts with 44% medical patients in Fagon and associates study (12) and 61% in our study. On the basis of our sensitivity analysis, the attributable increase in length of ICU stay and mortality is largely seen in medical patients, with essentially no effect seen in surgical patients. This may be due to differences in the underlying disease processes and chronic health status of surgical and medical patients. In summary, five of the six studies that used matching procedures to examine the attributable morbidity and mortality of VAP concluded that VAP does increase ICU length of stay. Only two of the studies did not find an excess mortality attributable to VAP (13, 27). In our study, the largest case control study of mortality attributable to VAP, we found that VAP may increase the risk of death by about 33% (an absolute risk increase of 5%). Our sensitivity analysis suggests that attributable risk may be greater in medical patients and in patients infected with high risk organisms. The multicenter nature of our study enhances the validity and generalizability of our findings. Understanding the true attributable mortality and length of stay associated with VAP allows physicians to provide accurate prognostic information to families of critically ill patients, identifies appropriate endpoints to be used in therapeutic and preventive trials in VAP, and better informs economic evaluations of interventions related to VAP. Given that VAP is associated with a substantial burden of illness for critically ill patients, studies aimed at explaining its underlying pathogenesis and evaluating approaches to its diagnosis, prevention, and treatment are warranted. Acknowledgment : The authors would like to thank the members of the Canadian Critical Care Trials Group who supported this study, particularly Drs. Gordon Guyatt, Andreas Freitag, Alicia Sarabia, Hugh Fuller, Maureen Meade, Mark Turner, and Kevin Gough. References 1. Rello, J., E. Quintana, V. Ausina, J. Castella, M. Luquin, A. Net, and G. Prats Incidence, etiology and outcome of nosocomial pneumonia in mechanically ventilated patients. Chest 100: Celis, R., A. Torres, J. M. Gateli, M. Amela, R. Rodrigues-Roisin, and A. Agusti-Vidal Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest 93: Craven, D. E., L. M. Kunches, D. A. Lichtenburg, N. R. Kollisch, A. Barry, T. C. Heeren, and W. R. McCabe Nosocomial infection and fatality in medical and surgical intensive care unit patients. Arch. Intern. Med. 148: Jimenez, P., A. Torres, R. Rodrigues-Roison, J. Puig de la Bellacasa, R. Aznar, and J. M. Gatell Incidence and etiology of pneumonia acquired during mechanical ventilation. Crit. Care Med. 17: Vincent, J. L., D. J. Bihari, P. M. Suter, H. A. Bruining, J. White, M. H. Nicolas-Chanion, M. Wolff, R. C. Spencer, and M. Hemmer The prevalence of nosocomial infection in intensive care units in Europe: results of the European prevalence of infection in intensive care (EPIC) study. J.A.M.A. 274: Bueno-Cavanillas, A., M. Delgado-Rodriguez, A. Lopez-Luque, S. Schaffino-Cana, and R. Galvez-Vargas Influence of nosocomial infection on mortality rate in an intensive care unit. Crit. Care Med. 22: Kollef, M. H Ventilator-associated pneumonia a multivariate analysis. J.A.M.A. 270: Torres, A., R. Aznar, J. P. Gatell, P. Jimenez, J. Gonzalez, A. Ferrer, R. Celis, and R. Rodriguez-Roisin Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am. Rev. Respir. Dis. 142: Kollef, M. H., P. Silver, D. M. Murphy, and E. Trovillion The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 108: Craven, D. E., L. M. Kunches, V. Kilinsky, D. A. Lichtenberg, B. J. Make, and W. R. McCabe Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am. Rev. Respir. Dis. 133: Fagon, J.-Y., J. Chastre, A. Vuagnat, J. L. Trouillet, A. Novara, and C. Gibert Nosocomial pneumonia and mortality among patients in intensive care units. J.A.M.A. 275: Fagon, J.-Y., J. Chastre, A. J. Hance, P. Montravers, A. Novara, and C. Gibert Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am. J. Med. 94: Papazian, L., F. Bregeon, X. Thirion, R. Gregoire, P. Saux, J. P. Denis, G. Perin, J. Charrel, J.-F. Dumon, J.-P. Affray, and F. Gouin Effect of ventilator-associated pneumonia on mortality and morbidity. Am. J. Respir. Crit. Care Med. 154: Cook, D. J., G. H. Guyatt, J. Marshall, D. Leasa, H. Fuller, R. Hall, S. Peters, F. Rutledge, L. Griffith, A. McLellan, G. Wood, and A. Kirby A comparison of sucralfate and ranitidine for prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N. Engl. J. Med. 338: Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman Apache II: a severity of diseases classification system. Crit. Care Med. 13: Marshall, J. C., D. J. Cook, N. V. Christou, G. R. Bernard, C. L. Sprung, and W. J. Sibbald Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit. Care Med. 23: Heyland, D. K., L. Griffith, and D. J. Cook The clinical and economic consequences of clinically important bleeding in the critically ill. Clin. Intensive Care 7: Leu, H., D. L. Kaiser, M. Mori, R. F. Woolson, and R. P. Wenzel Hospital-acquired pneumonia attributable mortality and morbidity. Am. J. Epidemiol. 129: Kuritz, S. J., and J. R. Landis Attributable risk estimation from matched case-control data. Biometrics 44:

8 1256 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL Trouillet, J. L., J. Chastre, A. Vuagnat, M. L. Joly-Guillou, D. Combaux, M. C. Dombret, and C. Gibert Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am. J. Respir. Crit. Care Med. 157: Alvarez-Lerma, F., for the ICU-Acquired Pneumonia Study Group Modification of empiric antibiotic treatment in patients with pneumonia acquried in the intensive care unit. Intensive Care Med. 22: Rello, J., P. Jubert, A. Artigas, M. Rue, and M. S. Niederman Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin. Infect. Dis. 23(5): Rello, J., A. Torres, M. Ricart, J. Valles, J. Gonzalez, A. Artigas, and R. Rodrigues Roisin Ventilator-associated pneumonia by Staphylococcus aureus. Am. J. Respir. Crit. Care Med. 150: Kollef, M. H., and S. Ward The influence of mini-bal cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 113: Mosconi, P., M. Langer, M. Cigada, and M. Mandelli Epidemiology and risk factors of pneumonia in critically ill patients. Eur. J. Epidemiol. 7: Fagon, J. Y., J. Chastre, A. J. Hance, Y. Domart, J. L. Trouillet, and C. Gibert Evaluation of clinical judgement in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest 103: Baker, A. M., J. W. Meredith, and E. F. Haponik Pneumonia in intubated trauma patients. Am. J. Respir. Crit. Care Med. 153: Cunnion, K. M., D. J. Weber, W. E. Broadhead, L. C. Hanson, C. F. Peiper, and W. A. Rutala Risk factors for nosocomial pneumonia: comparing adult critical care populations. Am. J. Respir. Crit. Care Med. 153: Craig, C. P., and S. Connelly Effect of intensive care unit nosocomial pneumonia on duration of stay and mortality. Am. J. Infect. Control 12: Kappstein, I., G. Schulgen, U. Beyer, K. Geiger, M. Schumacher, and F. D. Daschner Prolongation of hospital stay and extra costs due to ventilator-associated pneumonia in an intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. 11: Rouby, J. J., M. Martin de Lasale, P. Poete, M. H. Nicholas, L. Bodin, V. Jarlier, Y. Le Charpentier, J. Gorsset, and P. Viars Nosocomial bronchopneumonia in the critically ill: histologic and bacteriologic aspects. Am. Rev. Respir. Dis. 146: Torres, A., M. El-Ebiary, and L. Padro Validation of different techniques for the diagnosis of ventilator-associated pneumonia: comparison with immediate postmortem pulmonary biopsy. Am. J. Respir. Crit. Care Med. 149: Timsit, J. F., S. Chevret, J. Valcke, B. Misset, B. Renaud, F. W. Goldstein, P. Vaury, and J. Carlet Mortality of nosocomial pneumonia in ventilated patients: influence of diagnostic tools. Am. J. Respir. Crit. Care Med. 154: